Pharmaceuticals

Johnson & Johnson Submits Supplemental New Drug Application to Expand Use of HIV-1 Treatment Prescovix in Children Ages 6 and Older

bexib
By bexib 0 Min Read

A similar application has also been submitted to the EMA to expand the use of Prezcobix to treat HIV-infected children aged 6 years and older.

You Might Also Like

As layoffs continue and employees become paralyzed by fear of their jobs in 2024, how can leaders address critical real-world issues?

FDA Approves Geron’s Lytero for Treatment of Adults with Low-Risk Myelodysplastic Syndrome

Data presented at ASCO show improved complete response rates with Gemperli as first-line treatment for locally advanced rectal cancer in patients with mismatch repair deficiency

Discovering the Need for RNA Vaccines: Q&A with Thomas Rademacher, MD

Pharma Pulse 5/16/24: World Courier President talks supply chain risk mitigation, Walgreens brand naloxone available online and in stores, more

Share This Article
Previous Article How To Market Your Business on Social Media: 15 Easy Ways (2024)
Next Article Bank of Canada cuts interest rates for the first time in four years – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Valley Bank uses AI to reduce AML false positives by 65%
Banking
U.S. shipbuilding could accelerate this year
Manufacturing
New direction for the U.S. Senate Budget Committee
Insurance
How to print a shipping label
International Shipping